Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
Phase 1
Active, not recruiting
NCT04616534
| Condition | Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | National Cancer Institute (NCI) |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 14 participants |
|---|
| Interventions | Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Elimusertib, Gemcitabine |
|---|
| Start date | Jun 1, 2021 |
|---|
| Completion date | Apr 1, 2025 |
|---|
| Results posted | Jul 9, 2026 |
|---|
Summary
This phase I trial identifies the best dose, possible benefits and/or side effects of gemcitabine in combination with elimusertib (BAY 1895344) in treating patients with pancreatic, ovarian, and other solid tumors that have spread to other places in the body (advanced). Gemcitabine is a chemotherapy drug that blocks the cell from making DNA and may kill tumor cells. elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and elimusertib in combination may shrink or stabilize cancer.
Number of Patients on Treatment With Related Adverse Events
Adverse events were recorded between the first patient treated (June 2021) and 30 days out from the last patient ending treatment (October 2024) (3 years and 4 months). Adverse events were collected for a median of 88.5 days, ranging 58 - 315 days. · Participants
| Dose Escalation Level 1: 250 MG/M2 GEMCITABINE D1, 8 + 40 MG BAY1895344 (ELIMUSERTIB) BID D1-3,8-10 | 3 Participants |
|---|
| Dose Escalation Level B1: 100MG/M2 GEMCITABINE D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) BID D2-3, 9-10 | 2 Participants |
|---|
| Dose Escalation Level B4: 100MG/M2 GEMCITABINE D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) QD D2-3, 9-10 | 3 Participants |
|---|
| Dose Escalation Level B6: 175MG/M2 GEMCITABINE D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) QD D2-3, 9-10 | 3 Participants |
|---|
| Dose Escalation Level 1ESC: 175MG/M2 GEM D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) BID D2-3, 9-10 | 3 Participants |
|---|
Maximum Tolerated Dose (MTD)
The MTD was evaluated during the dose-escalation phase, occurring from the first patient on treatment (Jun '21) through the last patient's last dose (Sep '24) (3 years and 3 months). MTD was evaluated for a median of 58.5 days, ranging 28 - 285 days. · mg
| Dose Escalation Level 1: 250 MG/M2 GEMCITABINE D1, 8 + 40 MG BAY1895344 (ELIMUSERTIB) BID D1-3,8-10 | NA mg |
|---|
| Dose Escalation Level B1: 100MG/M2 GEMCITABINE D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) BID D2-3, 9-10 | NA mg |
|---|
| Dose Escalation Level B4: 100MG/M2 GEMCITABINE D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) QD D2-3, 9-10 | NA mg |
|---|
| Dose Escalation Level B6: 175MG/M2 GEMCITABINE D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) QD D2-3, 9-10 | NA mg |
|---|
| Dose Escalation Level 1ESC: 175MG/M2 GEM D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) BID D2-3, 9-10 | NA mg |
|---|
Overall Response Rate (ORR)
ORR was assessed from the time of the first patient on study (June 2021) through the last patient off study (October 2024). ORR was calculated for a median of 103 days, ranging from 30 - 312 days. · percent of participants
| Dose Escalation Level 1: 250 MG/M2 GEMCITABINE D1, 8 + 40 MG BAY1895344 (ELIMUSERTIB) BID D1-3,8-10 | 33.3 percent of participants |
|---|
| Dose Escalation Level B1: 100MG/M2 GEMCITABINE D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) BID D2-3, 9-10 | 0 percent of participants |
|---|
| Dose Escalation Level B4: 100MG/M2 GEMCITABINE D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) QD D2-3, 9-10 | 0 percent of participants |
|---|
| Dose Escalation Level B6: 175MG/M2 GEMCITABINE D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) QD D2-3, 9-10 | 0 percent of participants |
|---|
| Dose Escalation Level 1ESC: 175MG/M2 GEM D1, 8 + 20MG BAY 1895344 (ELIMUSERTIB) BID D2-3, 9-10 | 0 percent of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.